Rubicon Research Limited
1,436.35
INR
-13.90
(-0.96%)
ISIN
INE506V01022
Return %
Stock
S&P 500
1Y
134.76
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Parag Suganchand Sancheti
- Full Time Employees
- 1,303
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Thane India
- Website
- rubicon.co.in
- Similar Companies
- Business
- Rubicon Research Limited is an India-based specialty pharmaceutical and contract development and manufacturing organization (CDMO) focused on the development, manufacturing, and commercialization of differentiated pharmaceutical formulations and proprietary drug delivery technologies. Founded in 1999 and headquartered in Mumbai, India, the company operates across regulated international markets, including the United States, Canada, and Europe, as well as the domestic Indian pharmaceutical market. Rubicon Research operates across multiple therapeutic categories, including central nervous system, cardiovascular, oncology, anti-infective, pain management, gastrointestinal, and respiratory conditions. The company manufactures, markets, and provides a wide array of dosage forms and pharmaceutical services, including oral solid dosage forms comprising extended-release tablets, delayed-release tablets, orally disintegrating tablets, bilayered tablets, and capsules; oral liquid dosage forms comprising solutions, suspensions, syrups, and concentrates; respiratory and inhalation formulations comprising unit-dose and multi-dose nasal sprays, dry powder inhalers, and metered-dose inhalers; sterile and injectable formulations comprising ophthalmic drops and intrathecal injections; topical formulations; drug-device combination products; formulation and analytical development services utilizing novel drug delivery systems (NDDS); contract development and commercial-scale cGMP manufacturing; and regulatory dossier compilation and Abbreviated New Drug Application (ANDA) management. The company operates research and development centers in Thane, India, and Concord, Canada, alongside multiple cGMP-compliant manufacturing sites, and distributes products through subsidiaries including Validus Pharmaceuticals LLC, AdvaGen Pharma Limited, Rubicon Research Canada Ltd., and Arinna Lifesciences Limited. In recent corporate developments, Rubicon Research completed an Initial Public Offering (IPO) in October 2025, listing its equity shares on the National Stock Exchange of India and the Bombay Stock Exchange to fund capacity expansion and strategic initiatives. In April 2026, the company expanded its domestic presence in the central nervous system therapeutic segment by acquiring an 85% equity stake in Arinna Lifesciences Limited for approximately 175.92 crore Indian rupees. Additionally, the company bolstered its manufacturing footprint through the acquisition of a production facility from InvaTech Pharma Solutions, LLC in July 2026 and an oral solid formulation facility from Alkem Laboratories in Pithampur in June 2025, building on its acquisition of US-based Validus Pharmaceuticals to accelerate specialty branded product commercialization in North America.